diabetes glp 1 agonist Evolution of GLP‐1 Receptor Agonists for Treatment GLP1 Receptor Agonists—Effects beyond Obesity

By contrast, peptides such as PYY and apelin were discontinued primarily due to formulation limitations or tolerability at supraphysiologic dosespharmacologic rather than biological failuresand therefore meet criteria for re-evaluation

Papaetis GS, Kyriacou A (2022) GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: current research and future horizons

Although the roles of resistin, a hormone produced and secreted from mature adipocytes and macrophages 37,38 , may vary between physiological and pathophysiological states and among species 39 , several reports suggest that in mice, resistin directly affects glucose metabolism by antagonizing insulin action 40,41

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

20 After 52 weeks, steatohepatitis resolved without fibrosis progression in 44%, 56%, and 62% of participants receiving tirzepatide at doses of 5 mg, 10 mg, and 15 mg, respectively, compared to 10% in the placebo group